Mark Harries

7.3k citations
76 papers · 5.5k · 5 hit papers · h-index 37

Impact in

  • Oncology top 1%
    • Cancer Immunotherapy and Biomarkers
    • Cutaneous Melanoma Detection and Management
    • Breast Cancer Treatment Studies

Papers in

    • Cutaneous Melanoma Detection and Management 22
    • Cancer Immunotherapy and Biomarkers 12
    • Cancer Treatment and Pharmacology 5
    • HER2/EGFR in Cancer Research 4
    • Breast Cancer Treatment Studies 10

Mark Harries

74 papers receiving 5.3k citations

Mark Harries's Hit Papers

Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma 2024 · 105 citations
1050+2+5Years since publication200400600

Peers

Mark Harries
Comparison fields: 5 of 112
  • Oncology 2.2k
  • Cancer Research 919
  • Infectious Diseases 430
  • Reproductive Medicine 223
  • Immunology 370
Replace Pei Hui with:
Pei Hui United States
Francesco Angelo Mauri United Kingdom
Elin Solomonovna Gray Australia
Stefania Bellone United States
Gunnar Kvalheim Norway
Billel Gasmi United States
Kunyu Yang China
Peter George Maslak United States
Shuang Qin China
Desheng Weng China
Mark Harries relative to Pei Hui United States Pei Hui's profile →
Citations per field
00.5×2×3.5×
Pei Hui · 1×
Citations per year

Countries citing papers authored by Mark Harries

Since Specialization
Citations

This map shows the geographic impact of Mark Harries's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Harries with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Harries more than expected).

Fields of papers citing papers by Mark Harries

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Harries. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Harries. The network helps show where Mark Harries may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Harries, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Harries Line = papers co-authored together Mark Harries links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 76 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Hit paper breakdown →
2018707
2
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
Hit paper breakdown →
2021589
3
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
Hit paper breakdown →
2021497
4
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
Hit paper breakdown →
2022355
5 2019225
6 2013197
7 2018180
8 2002155
9 2002130
10 2014119
11 2002114
12 2015112
13
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Hit paper breakdown →
2024105
14 201398
15 200189
16 201189
17 201489
18 200587
19 201476
20 201172

About Mark Harries

Mark Harries is a scholar working on Oncology, Cancer Research, Immunology, Reproductive Medicine and Radiology, Nuclear Medicine and Imaging, having authored 76 papers that have together received 5.5k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (22 papers), Cancer Immunotherapy and Biomarkers (12 papers), Breast Cancer Treatment Studies (10 papers), Cancer Treatment and Pharmacology (5 papers), Melanoma and MAPK Pathways (5 papers), Ovarian cancer diagnosis and treatment (4 papers), Immunotherapy and Immune Responses (4 papers) and HER2/EGFR in Cancer Research (4 papers). The work is most often cited by research in Oncology (2.2k citations), Cancer Research (919 citations), Infectious Diseases (430 citations), Reproductive Medicine (223 citations) and Immunology (370 citations). Mark Harries has collaborated with scholars based in United Kingdom, France and Germany. Frequent co-authors include Martin Eric Gore, Ian Smith, PA Ellis, Mary K. Collins, Peter Harper, James F. Spicer, Stan B. Kaye, Arnie D. Purushotham, Katharine M. Acland and Hans Garmo. Their work appears in journals such as The Lancet Oncology, Annals of Oncology, British Journal of Cancer, Melanoma Research and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact